| 摘要: |
| 目的:分析国内外发表的关于沙利度胺致儿童不良反应的文献,了解沙利度胺在儿童风湿性疾病的用药安全性。方法:
以“沙利度胺” “ 儿童” “ adverse reaction” “ safety” “ thalidomide” “ children” “ pediatric” “ case report” 为关键词检索中国知网
(CNKI)、万方、PubMed 等数据库,对符合纳入标准的文献,提取药物安全性信息,并进行描述性分析。结果:共纳入18 篇文献,
累计病例263 例。沙利度胺引起儿童不良反应累及系统广泛,排名前5 位的依次是精神系统、神经系统、血液系统、消化系统、
皮肤系统,累计占比85. 16%。其中,周围神经病变发生率最高,占比19. 39%;严重不良反应占比17. 49%,以周围神经病变为
主,其发生与药物累积剂量相关。结论:沙利度胺用于儿童风湿性疾病,总体安全性较好,相关不良反应经停药或对症治疗后大
多可痊愈或好转。临床用药需关注药物累积剂量及周围神经病变的发生 |
| 关键词: 沙利度胺 风湿性疾病 全身型幼年特发性关节炎 周围神经病变 安全性 儿童 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2023.05.002 |
|
| 基金项目:上海市“医苑新星”青年医学人才培养资助计划,沪卫人事[2020]87 号 |
|
| Safety Analysis of Thalidomide in Systemic Juvenile Idiopathic Arthritis |
| Xie Ting, Sun Huajun, Li Zhiling, Liu Hongxia |
| (Shanghai Children’s Hospital, Children’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200062, China) |
| Abstract: |
| Objective: To analyze the literatures published at home and abroad on thalidomide induced adverse reactions in children,
and to provide references for the safety of thalidomide in children with systemic juvenile idiopathic arthritis. Methods: We searched
CNKI, Wanfang and PubMed databases with keywords “thalidomide” “children” “adverse reaction” “safety” “pediatric” “case
report” and some related Chinese expressions. The drug safety information was extracted from the literature that met the inclusion criteria
and conduct the descriptive analysis. Results: A total of 18 articles were included, and 263 cases were accumulated. Thalidomide
related adverse reactions involved a wide range of systems, and the top five were mental system, nervous system, blood system, digestive
system and skin system, accounting for 85. 16% in total. The incidence of peripheral neuropathy was the highest, accounting for
19. 39%. Serious adverse reactions accounted for 17. 49%, mainly peripheral neuropathy, which was related to the cumulative dose of
drugs. Conclusion: Thalidomide is generally safe for children with systemic juvenile idiopathic arthritis. Most of the related adverse
reactions can be cured or improved after drug withdrawal or symptomatic treatment. Clinical medication should pay attention to the
cumulative dose of drugs and the occurrence of peripheral neuropathy. |
| Key words: thalidomide rheumatic disease systemic juvenile idiopathic arthritis peripheral neuropathy safety children |
